The MHRA and Genomics England are investigating reports of pancreatitis linked to weight loss drugs like Mounjaro, Ozempic, and Wegovy, following numerous hospitalization cases. Despite hundreds of acute and chronic pancreatitis reports, causation has not been established. The study aims to explore potential genetic risks associated with these medications. Patients aged 18 and above with adverse reactions are encouraged to participate through the Yellow Card scheme, which seeks to enhance drug safety monitoring and minimize future risks. The overall message reflects that while these jabs show promise against obesity, they carry notable risks.
A study has been launched due to reports of serious side effects related to weight loss drugs potentially affecting the pancreas, prompting safety investigations.
Collection
[
|
...
]